Invitrogen to Acquire BiorReliance for $500 Million

In a move that will add drug development and manufacturing services to the company's portfolio, Invitrogen Corp. (Carlsbad, CA, USA) has agreed to acquire BioReliance Corp. (Rockville, MD, USA) for about US$500 million, including the assumption of around $70 million in debt.

BioReliance is a leading Contract Service Organization (CSO) that provides testing, development, and manufacturing services for biologic-based drugs to biotechnology and pharmaceutical companies worldwide. The company's services enable biotechnology and pharmaceutical firms to outsource the costly and complicated testing and manufacturing stages, which is particularly helpful to early-stage companies that may lack the staff, expertise, and financial resources to conduct many aspects of drug development in-house.

Upon completion of the acquisition, BioReliance will become part of Invitrogen's bioproduction business segment and, retaining its name, will focus both on its current line of services and on new developments. Invitrogen's current offerings for bioproduction include media, sera, reagents, customized packaging, cell lines, specialized testing, and technical and regulatory support.

"Through a broad range of service capabilities, BioReliance enables us to streamline the drug development process in the preclinical through production stages, helping bring biologic-based drugs to market more quickly and efficiently,” said Gregory T. Lucier, president and CEO of Invitrogen.




Related Links:
Invitrogen
BioReliance